Loading...
Market
Will BEAM-101 receive FDA approval for sickle cell therapy by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA approval announcements and press releases
Story
Beam Therapeutics' BEAM-101 Shows Superior Results at ASH 2024, Stock Rises
Dec 9, 2024, 12:57 PM
Beam Therapeutics Inc. has reported promising clinical data for its sickle cell gene therapy, BEAM-101, at the American Society of Hematology (ASH) 2024 conference. The therapy has shown an average of 64-65% fetal hemoglobin (HbF) levels in patients, significantly higher than its competitors Reni-cel and Casgevy. BEAM-101's efficient manufacturing process allows for fewer mobilization cycles, with an average of 1.4 cycles, compared to Reni-cel's 4.6 and Casgevy's 4.7. This efficiency could potentially expand the eligible patient population for gene editing therapies. Additionally, Beam's approach includes a novel conditioning regimen using an anti-CD117 antibody, aiming to reduce toxicity and increase the feasibility of the treatment. The company's stock saw a 6.5% increase following the announcement, reflecting positive market sentiment towards the potential of BEAM-101.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other major markets • 25%
Not approved in any major market • 25%
Universal gene therapy • 33%
Mutation-specific gene therapy • 33%
No approval • 34%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
